Metis Global Partners LLC Cuts Position in DexCom, Inc. (NASDAQ:DXCM)

Metis Global Partners LLC reduced its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 7.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 17,944 shares of the medical device company’s stock after selling 1,384 shares during the quarter. Metis Global Partners LLC’s holdings in DexCom were worth $2,227,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in DXCM. Valley National Advisers Inc. increased its holdings in DexCom by 73.0% in the 4th quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after purchasing an additional 103 shares in the last quarter. MV Capital Management Inc. grew its stake in shares of DexCom by 99.3% in the fourth quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock valued at $34,000 after buying an additional 138 shares in the last quarter. Washington Trust Advisors Inc. raised its holdings in shares of DexCom by 120.6% during the 4th quarter. Washington Trust Advisors Inc. now owns 353 shares of the medical device company’s stock valued at $44,000 after buying an additional 193 shares during the period. NBC Securities Inc. purchased a new stake in shares of DexCom during the 3rd quarter valued at about $47,000. Finally, Thompson Siegel & Walmsley LLC acquired a new position in DexCom during the 3rd quarter worth approximately $48,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Stock Performance

DexCom stock opened at $129.34 on Tuesday. The company has a market cap of $51.44 billion, a PE ratio of 83.65, a P/E/G ratio of 2.19 and a beta of 1.23. DexCom, Inc. has a 12 month low of $74.75 and a 12 month high of $142.00. The company has a fifty day moving average price of $132.38 and a two-hundred day moving average price of $120.80. The company has a debt-to-equity ratio of 1.08, a current ratio of 2.90 and a quick ratio of 2.53.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. DexCom had a return on equity of 31.01% and a net margin of 16.82%. The company had revenue of $921.00 million for the quarter, compared to analysts’ expectations of $911.20 million. Research analysts expect that DexCom, Inc. will post 1.78 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Canaccord Genuity Group lifted their price objective on shares of DexCom from $144.00 to $145.00 and gave the company a “buy” rating in a research note on Friday, April 26th. Raymond James boosted their price objective on shares of DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a report on Friday, April 26th. Royal Bank of Canada assumed coverage on DexCom in a research note on Tuesday, March 12th. They set an “outperform” rating and a $165.00 target price for the company. StockNews.com upgraded DexCom from a “hold” rating to a “buy” rating in a research note on Wednesday, May 1st. Finally, UBS Group raised their price objective on DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a research note on Wednesday, April 10th. Two analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, DexCom has a consensus rating of “Moderate Buy” and a consensus target price of $141.67.

Insiders Place Their Bets

In other news, CFO Jereme M. Sylvain sold 3,363 shares of the company’s stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $116.73, for a total value of $392,562.99. Following the completion of the sale, the chief financial officer now directly owns 71,142 shares of the company’s stock, valued at approximately $8,304,405.66. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, CFO Jereme M. Sylvain sold 3,363 shares of the business’s stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $116.73, for a total value of $392,562.99. Following the sale, the chief financial officer now owns 71,142 shares of the company’s stock, valued at approximately $8,304,405.66. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Michael Jon Brown sold 629 shares of the firm’s stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $126.25, for a total value of $79,411.25. Following the transaction, the executive vice president now directly owns 68,212 shares of the company’s stock, valued at approximately $8,611,765. The disclosure for this sale can be found here. In the last quarter, insiders sold 190,004 shares of company stock worth $25,610,270. 0.41% of the stock is owned by company insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.